Naoko Takebe to United States
This is a "connection" page, showing publications Naoko Takebe has written about United States.
Connection Strength
1.065
-
Early drug development in solid tumours: analysis of National Cancer Institute-sponsored phase 1 trials. Lancet. 2022 08 13; 400(10351):512-521.
Score: 0.135
-
Trends in Grade 5 Toxicity and Response in Phase I Trials in Hematologic Malignancy: 20-Year Experience From the Cancer Therapy Evaluation Program at the National Cancer Institute. J Clin Oncol. 2022 06 10; 40(17):1949-1957.
Score: 0.131
-
Defining, Identifying, and Understanding "Exceptional Responders" in Oncology Using the Tools of Precision Medicine. Cancer J. 2019 Jul/Aug; 25(4):296-299.
Score: 0.109
-
Identification of high-risk drugs related to chemotherapy-induced peripheral neuropathy?in Cancer Therapy Evaluation Program-sponsored phase I trials. Eur J Cancer. 2019 07; 115:111-119.
Score: 0.108
-
Analysis of esophagogastric cancer patients enrolled in the National Cancer Institute Cancer Therapy Evaluation Program sponsored phase 1 trials. Gastric Cancer. 2017 May; 20(3):481-488.
Score: 0.089
-
Radiation-Therapeutic Agent Clinical Trials: Leveraging Advantages of a National Cancer Institute Programmatic Collaboration. Semin Radiat Oncol. 2016 10; 26(4):271-80.
Score: 0.088
-
Perspectives on research activity in the USA on Cancer Precision Medicine. Jpn J Clin Oncol. 2016 Feb; 46(2):106-10.
Score: 0.085
-
Recent innovations in the USA National Cancer Institute-sponsored investigator initiated Phase I and II anticancer drug development. Jpn J Clin Oncol. 2015 Nov; 45(11):1001-6.
Score: 0.084
-
Phase II Study of Ulixertinib in Children and Young Adults With Tumors Harboring Activating Mitogen-Activated Protein Kinase Pathway Alterations: APEC1621J of the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. JCO Precis Oncol. 2024 Jun; 8:e2400103.
Score: 0.038
-
Tazemetostat for tumors harboring SMARCB1/SMARCA4 or EZH2 alterations: results from NCI-COG pediatric MATCH APEC1621C. J Natl Cancer Inst. 2023 11 08; 115(11):1355-1363.
Score: 0.037
-
Actionable Tumor Alterations and Treatment Protocol Enrollment of Pediatric and Young Adult Patients With Refractory Cancers in the National Cancer Institute-Children's Oncology Group Pediatric MATCH Trial. J Clin Oncol. 2022 07 10; 40(20):2224-2234.
Score: 0.033
-
The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst. 2021 01 04; 113(1):27-37.
Score: 0.030
-
Defining precision: The precision medicine initiative trials NCI-MPACT and NCI-MATCH. Curr Probl Cancer. 2017 May - Jun; 41(3):182-193.
Score: 0.023
-
Pediatric oncology enters an era of precision medicine. Curr Probl Cancer. 2017 May - Jun; 41(3):194-200.
Score: 0.023
-
National Cancer Institute's Precision Medicine Initiatives for the new National Clinical Trials Network. Am Soc Clin Oncol Educ Book. 2014; 71-6.
Score: 0.019
-
NCI-RTOG translational program strategic guidelines for the early-stage development of radiosensitizers. J Natl Cancer Inst. 2013 Jan 02; 105(1):11-24.
Score: 0.017
-
NIH and NCI support for development of novel therapeutics in gynecologic cancer: a user's guide. Gynecol Oncol. 2010 Feb; 116(2):177-80.
Score: 0.014